|
Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma. |
|
|
|
Consulting or Advisory Role - Celgene |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
Honoraria - Mundipharma; Roche; Takeda |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Janssen-Cilag; Mundipharma; Roche; Takeda; Teva |
Research Funding - Bayer (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celltrion (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Mundipharma (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Celgene; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
Research Funding - Celgene; GlaxoSmithKline; Janssen; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Mundipharma; Novartis; Spectrum Pharmaceuticals; Takeda; Teva |
Research Funding - Celgene; Eisai; Gilead Sciences; Janssen; Novartis; Pfizer; Pharmacyclics; Roche Pharma AG; Sandoz; Spectrum Pharmaceuticals; Takeda; Teva |
|
|
|
Consulting or Advisory Role - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Roche Pharma AG |
|
|
|
|
|
|
|
Marie-Laure Casadebaig Bravo |
|
|
|
Consulting or Advisory Role - Celgene; Janssen; Roche Pharma AG |
Research Funding - Celgene |
Patents, Royalties, Other Intellectual Property - Invivoscribe |
|
|
Leadership - Celgene; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Celgene; Pfizer; Roche Pharma AG |